Suscribirse

Use of Statins for Primary Prevention: Selection of Risk Threshold and Implications Across Race and Gender - 12/10/18

Doi : 10.1016/j.amjmed.2018.05.029 
Abhishek Goyal, MD, MPH a, Howard A. Cooper, MD b, Wilbert S. Aronow, MD b, Prashant Nagpal, MD c, Srikanth Yandrapalli d, Christopher C. Nabors, MD, PhD d, , William H. Frishman, MD d
a Division of Internal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Mass 
b Division of Cardiology, Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla 
c Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City 
d Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla 

Requests for reprints should be addressed to Christopher C. Nabors, MD, PhD, Department of Medicine, New York Medical College, Taylor Care Center 316C, 100 Woods Road, Valhalla, NY 10595.100 Woods RoadValhalla,NY10595

Abstract

Background

The 2016 U.S. Preventive Services Task Force (USPSTF) guidelines for primary prevention statin therapy are more restrictive than the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines. There are important differences in how application of the risk thresholds from these guidelines would impact particular segments of the U.S. population.

Methods

Data from the National Health and Nutrition Examination Survey (2005-14) were used to determine statin eligibility across age, gender, and racial or ethnic group using criteria from the 2013 ACC/AHA and 2016 USPSTF guidelines. Proportions of the study population eligible for statins under the ACC/AHA 5% and 7.5% risk thresholds were compared with those eligible under the 2016 USPSTF 10% guidelines.

Results

Of the 5388 study participants, 34% were eligible for statin therapy under the USPSTF guideline compared with 43% under the Class I (7.5%) ACC/AHA treatment threshold and 53% under the Class IIa (5%) ACC/AHA treatment threshold. Moving from the USPSTF 10% threshold to the ACC/AHA 5% threshold increased statin eligibility for males ages 40-59 from 26%-48% (whites), from 19%-43% (Hispanics), and from 33%-74% (blacks). A similar disproportionate but less pronounced effect was seen when different risk thresholds were used for statin eligibility among women ages 40-59 across differing races and ethnicities.

Conclusions

In this sample of U.S. adults from the National Health and Nutrition Examination Survey database, full implementation of the higher USPSTF statin treatment threshold could lead to less overall statin use and disproportionately lower statin use among non-Hispanic blacks.

El texto completo de este artículo está disponible en PDF.

Keywords : Atherosclerotic cardiovascular disease, Primary prevention, Statin


Esquema


 Funding: None.
 Conflict of Interest: None.
 Authorship: All authors had access to the data and a role in writing this manuscript.


© 2018  Elsevier Ltd. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 131 - N° 10

P. 1234-1237 - octobre 2018 Regresar al número
Artículo precedente Artículo precedente
  • Diastolic Hypotension May Attenuate Benefits from Intensive Systolic Targets: Secondary Analysis of a Randomized Controlled Trial
  • Todd C. Lee, Rodrigo B. Cavalcanti, Emily G. McDonald, Louise Pilote, James M. Brophy
| Artículo siguiente Artículo siguiente
  • Association of Dairy Consumption and 24-Hour Blood Pressure in Older Adults with Hypertension
  • Alberto Lana, Jose R. Banegas, Pilar Guallar-Castillón, Fernando Rodríguez-Artalejo, Esther Lopez-Garcia

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.